Volume 35, Issue 1, March 2024

Sign in to download the Issue in PDF format.

Mediterr J Rheumatol 2024;35(1):66-72
State of the Art Review on the Treatment of Psoriatic Disease
Authors Information

Eleftherios Pelechas1, Evripidis Kaltsonoudis1, Michalis P. Migkos1, Nikolaos Koletsos1, Panagiota G. Karagianni2, Alexandros A. Drosos1, Paraskevi V. Voulgari1

1Department of Rheumatology, Medical School, University of Ioannina, Ioannina, Greece

2Department of Microbiology, Medical School, University of Ioannina, Ioannina, Greece

E Pelechas, E Kaltsonoudis, MP Migkos, N Koletsos, PG Karagianni, AA Drosos, PV Voulgari


Introduction: Psoriasis is an inflammatory skin disease that in some cases is accompanied by systemic manifestations. Given the varied clinical manifestations, the term psoriatic disease probably better reflects the clinical picture of these patients. Literature review: In most cases, the skin lesions precede joint involvement as well as other potentially involved organs such as the intestine and the eye. Various immune-mediated cellular pathways such as that of TNFα, IL-23, IL-17 as well as other cytokines are involved in the pathophysiology of the psoriatic disease. Future insights: A better understanding of the way they interfere with our immune system has led to remarkably better disease control and outcomes. This review aims to highlight the newest treatments for psoriatic disease, which are expected to significantly reduce unmet needs and treatment gaps.


Cite this article as: Pelechas E, Kaltsonoudis E, Migkos MP, Koletsos N, Karagianni PG, Drosos AA, Voulgari PV. State of the Art Review on the Treatment of Psoriatic Disease. Mediterr J Rheumatol 2024;35(1):66-72.

Article Submitted: 04 Jan 2023; Revised Form: 13 Oct 2023; Article Accepted: 04 Dec 2023; Available Online: 31 Jan 2024

This work is licensed under a Creative Commons Attribution 4.0 International License.

©2024 The Author(s).